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     The escalating number of multidrug resistant pathogens has demanded the swift 
development of new and potent antibiotics (ref. 2).  Metallo-β-lactamases (MBLs) 
continue to evolve, rendering the latest generation of carbapenem antibiotics useless 
(ref. 8).  SPM-1, a recently discovered MBL, was isolated from a juvenile leukemia 
patient residing in a hospital in San Palo, Brazil just prior to the patient succumbing 
to septicemia brought on by Pseudomonas aeruginosa expressing SPM-1 (ref. 8).   
Screening of the Johns Hopkins Compound library of 1,514 FDA or FAD approved 
drugs (ref. 1) identified a novel SPM-1 inhibitor that is synergistically compatible 
with meropenem.  Using clinically achievable concentrations, meropenem coupled 
with nadifloxacin inhibits Pseudomonas aeruginosa expressing SPM-1.   This 
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shotgun approach to new drug discovery provided a prompt solution to the grave 
problem of antibiotic resistant pathogens that are thriving in hospitals today.  
     The challenges associated with drug development are vast and have been well 
documented, but a straightforward, cost-effective alternative already exists: screening 
existing drugs for novel uses.  For example, a screen of the Johns Hopkins Clinical 
Compound Library (JHCCL; a publicly available collection of >1,500 existing drugs) 
found astemizole, a common over the counter antihistamine, to effectively kill the 
Plasmodium parasite responsible for causing malaria, including chloroquine resistant 
strains (ref. 1).  Here we apply this strategy to target bacterial antibiotic resistance. 
     New antibiotics are needed to combat the increasing number of resistant bacterial 
strains that are prevalent in hospitals today. Unfortunately, the discovery and 
development of new antibiotics is not meeting the clinical need due to increasing 
resistance (for a review see ref. 2) and the growing numbers of immunocompromised 
individuals with HIV, patients undergoing cancer chemotherapy and burn wound patients 
are now at risk from hospital-acquired (nosocomial) infections. It is estimated that 50% 
of all deaths caused by burns are the result of intractable bacterial infections with a high 
occurrence in patients infected with P. aeruginosa (ref. 3).  P. aeruginosa is a versatile 
environmental organism that can subsist over a wide range of nutrient sources and 
conditions and that can form biofilms in which a significant portion of the bacterial 
population can produce exopolysaccharides that prohibit phagocytosis (ref. 4).  These 
characteristics allow P. aeruginosa to flourish in hospital environments, making it the 
second most common nosocomial bacterial pathogen.  Nosocomial P. aeruginosa strains 
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are often resistant to multiple antibiotics (ref. 5) resulting in chronic infections with the 
highest mortality rate (ref. 6).   
     One mechanism of antibiotic resistance is the hydrolytic inactivation of β-lactam 
antibiotics by MBLs (ref. 7).  MBL enzymes such as SPM-1, originally identified from a 
P. aeruginosa clinical isolate (ref. 8), are class B β-lactamases that confer resistance in 
bacteria to a wide range of β-lactam antibiotics, including carbapenems. β-lactams remain 
the most widely prescribed class of antibiotics while the carbapenems are often the most 
(or only) effective antibiotics for treating resistant organisms such as P. aeruginosa.  
New therapeutic strategies for the treatment of  infections by antibiotic-resistant bacteria, 
particularly carbapenem-resistant P. aeruginosa, in burn centers and hospital settings in 
general are urgently required (ref. 9). 
     One approach to extend the utility of carbapenems and other β-lactam antibiotics is 
through combination therapy.  Examples include augmentin™ (amoxicillin-potassium 
clavulanate) and Unasyn™ (ampicillin-sulbactum) that combine a β-lactam antibiotic 
with a potent β-lactamase inhibitor.  However, such treatments are ineffective against 
many β-lactamases, including MBLs such as SPM-1.  To date, only three modest SPM-1 
inhibitors have been reported and are not clinically useful (ref. 10).  The JHCCL 
collection contains 1,514 existing drugs that are either FDA approved and/or Foreign 
Approved Drugs (FAD) (ref. 1).  Using the cephalosporin nitrocefin as a substrate, the 
JHCCL was screened for inhibitors of SPM-1.  Out of three compounds that were defined 
as potential leads, nadifloxicin, a topical fluoroquinolone used in creams to treat acne 
vulgaris and bacterial skin infections, was studied further.  Nadifloxacin has broad-
spectrum antibacterial activity against aerobic Gram-positive, Gram-negative and 
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anaerobic bacteria, and exhibits a Ki of 9.8 + 2.3 μM (~ 3.5 μg/mL) for SPM-1 displaying 
a mixed mode of inhibition (ref. 11).   
     The ideal MBL inhibitor should reverse carbapenem resistance in a clinically relevant 
bacterial strain.  The carbapenem meropenem is indicated as empirical therapy in both 
adults and children with a broad range of serious infections including complicated skin 
and skin structure infection (cSSSI) (ref. 12).  In one of the largest studies conducted to 
date of hospitalized patients with cSSSI, 500 mg of meropenem administered every 8 hrs. 
was found to be safe and effective (ref. 13).  However, such therapy would be ineffective 
in patients harboring carbapenem resistant bacterial strains such as P. aeruginosa.  P. 
aeruginosa expressing SPM-1 exhibits a minimum inhibition concentration (MIC) for 
meropenem of 500 μg/mL, approximately a 100-fold increase in resistance compared to 
wild type P. aeruginosa strain PA01.  The SPM-1 inhibitor nadifloxacin exhibits 
profound synergy with meropenem at clinically achievable concentrations near the Ki  
value (Fig. 1) in a P. aeruginosa strain expressing SPM-1.    
     Fluoroquinolones are effective antibacterial agents which are generally well tolerated 
and in some cases, have been life saving (ref 14).  Nadifloxacin targets DNA gyrase, 
while carbapenems target biosynthesis of the bacterial cell wall.  Thus, the probability of 
emerging antibiotic resistance against both mechanisms is very low.  Synergy of 
cephalosporins and fluoroquinolones in P. aeruginosa has been reported (ref. 15) but not 
in highly resistant strains to carbapenems as described in this report.  Of the 1,514 
compounds in the JHCCL, 19 belong to the quinolone family; only nadifloxacin 
exhibited significant SPM-1 inhibition indicating a highly specific interaction with the 
enzyme target.  The capability of nadifloxacin, an antibiotic already approved for clinical 
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use, to reverse meropenem resistance in P. aeruginosa revealed in this study suggests a 
new combination therapy for potentially lethal infections in burn patients.   
Methods 
Screening of JHCC 
     The Johns Hopkins Clinical Compound Library (JHCCL) version 1.0 containing 1,514 
drugs was screened for inhibitory activity against purified SPM-1.  Lead compounds, 
defined as ≥ 50% inhibition of SPM-1 at a final concentration of 40 µM, were identified 
by measuring the hydrolysis of the chromogenic substrate nitrocefin (Calbiochem, San 
Diego, CA, USA), at 490 nm, using a PowerWaveTM microplate spectrophotometer 
(BioTek, Winooski, VT, USA).  All assays were carried out in 50 mM cacodylic acid 
buffer (100 µM ZnCl2, 0.1% BSA, pH 7.0).  SPM-1 enzyme (final concentration of 10 
nM) was pre-incubated with each compound in the JHCCL (final concentration 40 µM) 
for 30 minutes at 25°C.  Initial velocities were measured following the addition of 
substrate (final concentration 20 µM).  The final concentration of DMSO in the assay did 
not exceed 2.4% (vol/vol).   
Ki Determination  
     The Ki  value for nadifloxacin was calculated by varying substrate and inhibitor 
concentrations using Lineweaver-Burk plots of 1/V versus 1/S.  Data was fitted using 
SigmaPlot 8.0 (SPSS Inc., Chicago, IL, USA).  The reported Ki value represents three 
independent experiments with four replicates in each experiment.   
Synergy experiments 
     P. aeruginosa, ATCC strain PA01, was transformed with the SPM-1(pK18) clone (ref. 
16 and 17)  by electroporation in 0.2 cm cuvettes at 2.5 kV, 25 µF and 200 Ω to generate 
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a pulse of approximately 6 msec.  After electroporation, the cells were resuspended in 1 
mL of LB broth and incubated at 37ºC for 1 hour with vigorous shaking.  500 µl of cell 
suspension was plated on LB agar supplemented with meropenem (50 µg/mL) for 
transformant selection, and incubated at 37ºC for 24 hrs (ref. 18).  The meropenem 
resistant colonies were collected separately and inoculated into LB broth supplemented 
with meropenem (50 µg/mL). 
     Minimum inhibitory concentrations (MIC) were determined using a checkboard 
microtitration in a 96-well plate format.  Briefly, nadifloxacin (LKT Laboratories, St. 
Paul, MN, USA) and meropenem (Sequoia Research Products, Oxford, UK) at varying 
concentrations were added to a 1:20 dilution of overnight culture.  The plates were 
incubated for 18 hrs. at 37ºC with shaking.  MIC was determined by measuring OD at 
650 nm.  To calculate synergy, nadifloxacin and meropenem were tested alone.   The 
fractional inhibitory concentration (FIC) was calculated using; 
     Combined FIC of drug A + B ≤ 0.5 for synergy (inhibitory concentration of A divided 
by MIC of A) + (inhibitory concentration of B divided by MIC of B). 
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Figure 1.  Isobologram of meropenem in combination with nadifloxacin against P. aeruginosa 
expressing SPM-1 demonstrating synergy.  Chemical structures of meropenem (x axis) and 
nadifloxacin (y axis) are shown.  FIC represents fractional inhibitory concentration. 
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